DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Dengue Hemorrhagic Fever — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDengue Hemorrhagic Fever maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dengue hemorrhagic fever is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phospholipase C epsilon 1 (PLCE1) — PLCE1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2C5L · 1.9 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
No drug is approved to treat dengue virus infection. A 2013 review states that drug development is hindered by a poor understanding of disease progression and the causes of vascular leakage. Most efforts have focused on viral targets, and the authors conclude that only human trials of safe compounds with demonstrated antiviral activity can determine whether a direct-acting antiviral will work.
A 2015 case report describes a 30-year-old male with dengue haemorrhagic fever who suffered an intracerebral haemorrhage. The report cites an overall mortality for dengue infection of 1–5% without treatment and less than 1% with adequate treatment, but notes that severe disease carries a mortality of 26%. Haemorrhagic complications causing intracerebral haemorrhage are described as rare but fatal.
A 2021 review states that more than 500,000 hospitalisations occur every year due to dengue virus infection, with increased threats of dengue haemorrhagic fever and dengue shock syndrome during secondary infections. The review notes that the approved vaccine is harmful in the naïve population with respect to initiating primary dengue infection. It reports that several clinically approved drugs have entered human clinical trials, and it addresses repurposing drug targets investigated in dengue haemorrhagic fever and dengue shock syndrome patients. The review does not report any positive results from those trials.
What is still missing is a clear understanding of the disease mechanisms that cause vascular leakage, a proven direct-acting antiviral from human trials, and any repurposed drug that has shown a reduction in clinical severity in a completed trial. The 2021 review does not state that any drug has succeeded.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Orphan Drugs · 2013 · 4 citations · open access
Difficulties and advancements in developing drugs for the treatment of dengue fever
AbstractDengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans.There are no drugs available to treat dengue virus infection.Here, we discuss the strategies and challenges to develop dengue drugs.Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage.Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges.Despite various challenges, great progresses have been made towards the development of dengue therapy.Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.
Journal of Evolution of Medical and Dental Sciences · 2015 · 0 citations · open access
DENGUE HEMORRHAGIC FEVER: AN UNUSUAL CAUSE OF INTRACEREBRAL HEMORRHAGE
AbstractDengue is the most important arboviral disease of humans. An estimated 50 million dengue infections and 500,000 Dengue Hemorrhagic Fever cases occur annually, particularly in south-east Asia, the western Pacific and the Americas. [1] The overall mortality in dengue infection is 1-5% without treatment and less than 1% with adequate treatment however severe disease carries a mortality of 26%. [2],[3] Hemorrhagic complications causing intracerebral hemorrhage is rare but fatal. We report a case of 30 year old male with dengue haemorrhagic fever with intracerebral hemorrhage.
Frontiers in anti-infective drug discovery · 2021 · 0 citations
Dengue Hemorrhagic Fever: The Potential Repurposing Drugs
AbstractDengue is the most significant arthropod-borne viral infection of humans. More than 3.8 billion people live in endemic areas. Dengue virus infection (DVI) results in more than 500,000 hospitalizations every year, with increased threats of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) during secondary infections. In spite of the high disease burden of the dengue virus, there are no specific antiviral drugs available, and the approved vaccine is harmful in the naïve population with respect to the initiation of primary dengue infection. Several clinically approved drugs have entered human clinical trials. This review addresses the repurposing drug targets that have been investigated in DHF and DSS patients. Furthermore, their essential antiviral action and specific classes of clinically approved drugs have been clarified. These clinical trials' outcomes can enhance our understanding of the antiviral activities of these repurposing drugs to alleviate the clinical severity of dengue viral infection.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
